Cellectar Biosciences Secures $35M in Highly Dilutive Offering to Fund Phase 3 Trial

summarizeSummary

Cellectar Biosciences closed a highly dilutive $35 million registered direct offering and private placement at a deep discount to fund its Phase 3 clinical trial, with a major investor gaining a board seat.

check_boxKey Events

• Secured $35 Million in Gross Proceeds

  The company completed a registered direct offering and concurrent private placement, raising approximately $35 million in gross proceeds. This follows a 424B5 filing on May 6, 2026, which indicated an approximate $32 million raise, with this filing confirming the final terms and closing.

• Highly Dilutive Offering at Deep Discount

  The offering included 1,618,053 common shares, 2,116,887 unregistered common shares, 9,471,086 pre-funded warrants, and 13,206,026 milestone warrants. The pricing for institutional investors was $2.65 per share/equivalent, and for management, it was $2.88 per share/warrant, both representing a deep discount to the current stock price of $3.36. The total potential shares from this offering are significantly higher than the current outstanding shares, indicating substantial dilution.

• Funds to Advance Phase 3 Clinical Trial

  Net proceeds from the offering will be used for working capital and general corporate purposes, specifically to support the initiation of a Phase 3 trial for iopofosine I 131 in Waldenström macroglobulinemia (WM) patients.

• Board Seat Granted to Major Investor

  Nantahala Capital Management, LLC, a participating institutional investor, is entitled to designate one member to the company's Board of Directors, subject to board approval and independence requirements.

auto_awesomeAnalysis

Cellectar Biosciences has finalized a registered direct offering and concurrent private placement, raising approximately $35 million in gross proceeds. This substantial capital infusion, significantly larger than the company's current market capitalization, is critical for funding the planned Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia. However, the offering is highly dilutive, with shares and pre-funded warrants issued at $2.65, a deep discount to the current stock price of $3.36. The total number of shares and equivalents issued or potentially issuable upon exercise of warrants is more than double the current outstanding shares. A key institutional investor, Nantahala Capital Management, LLC, will also gain a board seat, indicating increased investor oversight. This financing, while necessary for advancing the clinical pipeline, comes at a significant cost to existing shareholders due to the deep discount and substantial dilution.